Tryp Therapeutics Inc (TRYP) Corporate Media Kit

indications for the Company’s Phase 2a clinical trials. The company is also developing a proprietary, psilocybin-based drug product, TRP-8803, with a novel formulation and route of administration that is expected to improve the patient experience and that will be used for Phase 2b stud- ies and beyond. Based on existing preclinical and clinical data for its active pharmaceu- tical ingredients, Tryp intends to seek FDA approval to proceed directly to Phase 2 clinical trials evaluating TRP-8802 as a treatment for fibro- myalgia. In addition, the company will seek to initiate Phase 2a clinical trials for TRP-8802 in the treatment of eating disorders and certain forms of chronic pain including phantom limb pain and complex regional pain syndrome.